Throughout the treatment timeline, ORBERA® was well tolerated by most patients. Common side effects include nausea, vomiting, and gastric pain and usually stops within one to two weeks after placement. Doctors report that patients view their ORBERA® in a very positive light as transient side effects have decreased, judging it as “good”, “very good” or “excellent”.
Smooth and soft surface to reduce the possibility of ulcers;
The ideal sterile solution for filling the balloon;
It can be filled with a volume between 400-700cc;
To provide easy viewing inside the stomach.
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing more than 600 million people worldwide, as well as other gastrointestinal disorders.
Our device-based therapies are an alternative to invasive surgical procedures, thus reducing potential complications and overall healthcare costs. Apollo products are available around 80 countries.